INTRODUCTION The ability to regenerate complex body parts varies considerably in the animal kingdom. While planarian and hydra are able to regenerate their entire bodies, many avian and mammalian species mostly stop at the wound healing stage without a reparative regeneration process (1). This disparity may result from complexity differences among organisms by nature, yet it leaves us the hope that we may learn from highly regenerative species to improve our own regenerative potential
TG Therapeutics reports development for Umbralisib TG Therapeutics Inc.
On July 31, 2020, the FDA granted accelerated approval to the combination of tafasitamab (Monjuvi) and lenalidomide (Revlimid) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant.1 The approval was granted based on findings from the phase 2 L-MIND trial that assessed the safety and efficacy of the combination of tafasitamab and lenalidomide in patients with relapsed/refractory DLBCL who had received 2 prior lines of therapy, including a CD20-directed therapy, and who are ineligible for high-dose chemotherapy and autologous stem cell transplantation. In this trial, the trial induced an objective response rate of 60%, with complete responses in 43%. The median duration of response was 21.7 months and 72% had a response lasting at least a year.2 The median progression-free survival (PFS) was 12.1 months with a 50% PFS rate at 1 year and 46% at 18 months.
A potentially safer, more effective chemotherapy treatment for patients with blood-related cancers, such as leukemia, who need a particular bone marrow transplant procedure is under study at the University of Arizona Health Sciences. The procedure is known as a haploidentical (half-matched) bone marrow transplantation, or "haplo-BMT," providng an alternative source of stem cells for patients who need a bone marrow transplant but are unable to find a perfect or near-perfect donor match for human leukocyte antigens (HLA)
Roots Analysis has announced the addition of Cell Therapy Manufacturing Market (2nd Edition), 2018-2030 report to its list of offerings.
FDA Approves Tafasitamab-cxix in Combination With Lenalidomide for the Treatment of DLBCL A humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, tafasitamab-cxix received accelerated approval based on overall response rate (ORR).
As you were browsing http://www.streetinsider.com something about your browser made us think you were a bot. If you are interested in http://www.streetinsider.com content, APIs are available
The self-eating process in embryonic stem cells known as chaperone-mediated autophagy (CMA) and a related metabolite may serve as promising new therapeutic targets to repair or regenerate damaged cells and organs,Penn Medicineresearchers show in a new study published online inScience. Human bodies contain more than 200 different types of specialized cells. All of them can be derived from embryonic stem (ES) cells, which relentlessly self-renew while retaining the ability to differentiate into any cell type in adult animals, a state known as pluripotency.
TMR Research announces a new report on the global stem cell assay market. The report examines the historical growth trajectory exhibited by the global stem cell assay market and its latest figures, and further provides reliable forecasts for the stem cell assay market based on complete analysis of the markets database.
Biopharma companies that are focused on cell therapies have reported promising clinical trial results in their ability to treat acute respiratory distress syndrome (ARDS), a condition that has shown to be a significant contributor to higher mortality in COVID-19 cases. In an Alliance for Regenerative Medicine (ARM) webinar on the topic, Michael Lehmicke, director, science and industry affairs at ARM, noted that developers are utilizing mesenchymal stem cells (MSCs) and other stromal cells to treat ARDS caused by COVID-19. The number of clinical trials now underway continues to increase with many more at the preclinical stage
Recent Comments